• Kadhim Ali Kadhim Department of Clinical Pharmacy, College of Pharmacy, Al-Mustansiriyah University, Baghdad, Iraq.
  • Lubab Tarek Nafea Department of Clinical Pharmacy, College of Pharmacy, Al-Mustansiriyah University, Baghdad, Iraq.
  • Gaith Ali Gasim Department of Pharmacology, College of Pharmacy, Al-Mustansiriyah University, Baghdad, Iraq.
  • Esraa Abdul-al Hameed Consultant Endocrinology F.I.C.M.S. at Child Central Teaching Hospital, Baghdad, Iraq.
  • Hayder A Fawzi Clinical Pharmacist, Baghdad Medical City, Baghdad, Iraq.


Objective: The objective of this study is to estimate the effect of Vitamin D3 supplementation on endogenous Vitamin D3 level and inflammatory biomarkers in newly diagnosed pediatric patients.

Methods: The patients were given oral Vitamin D3, and they divided into three groups: The first group (25 healthy pediatrics), the second group (25 newly diagnosed pediatric patients) treated with daily insulin regimen only, and the third group (25 newly diagnosed pediatric patients) treated with Vitamin D3 (2000 IU/day) with daily insulin regimen; all patients were treated for 90 days; and blood samples were taken at baseline and after 45 days and 90 days of starting Vitamin D3 to assess its potential effect on the levels of Vitamin D, serum calcium, serum alkaline phosphatase levels, and other inflammatory markers.

Results: The results of the current study showed that serum IL-1β significantly declined in patients receiving Vitamin D3, while serum Vitamin D3, serum calcium, and interleukins-4 were significantly increased in patients receiving Vitamin D3.

Conclusion: Vitamin D3 in a daily dose of 2000 IU/day for 90 days results in favorable immune response and increase of serum Vitamin D3 for pediatric new diagnosed Type 1 diabetes mellitus patients.

Keywords: Type 1 diabetes mellitus, Vitamin D3, Interleukin-4, Interleukin-1β.

Author Biography

Hayder A Fawzi, Clinical Pharmacist, Baghdad Medical City, Baghdad, Iraq.

Clinical Pharmacy Board 

Clinical Research 


1. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34 Suppl 1:S11-61.
2. Hallak A, Malhis M, Abajy MY. Vitamin-D deficiency and risk of acute coronary syndrome. Int J Pharm Pharm Sci 2018;10:171-5.
3. Abbas RS, Abdulridha MK, Shafek MA. Clinical evaluation of potential anti-inflammatory effect of Vitamin D3 adjuvant therapy for chronic asthma in iraqi patients. Int J Pharm Pharm Sci 2017;9:139-44.
4. Vlassara H, Palace M. Diabetes and advanced glycation endproducts. J Int Med 2002;251:87-101.
5. Hamid S, Sahib HB, Fawzi HA, Nori AY. Medication adherence and glycemic control in newly diagnosed diabetic patients. Int J Res Pharm Sci 2018;9:816-20.
6. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther 2008;88:1254-64.
7. Winer S, Tsui H, Lau A, Song A, Li X, Cheung RK, et al. Autoimmune islet destruction in spontaneous Type 1 diabetes is not β-cell exclusive. Nat Med 2003;9:198.
8. Atkinson MA. The pathogenesis and natural history of Type 1 diabetes. Cold Spring Harb Perspect Med 2012;2:a007641.
9. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998;55:1139-49.
10. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of Vitamin D and risk of Type 1 diabetes: A birth-cohort study. Lancet 2001;358:1500-3.
11. Alizzi FJ, Abbas WA, Fawzi HA. Assessment of the role of cholecystokinin in hyperemesis gravidarum and correlation with its severity. J Pharm Sci Res 2018;10:272-5.
12. Tard C, Rouxel O, Lehuen A. Regulatory role of natural killer T cells in diabetes. Biomed J 2015;38:484-95.
13. Adrian V, Romulus T. Pathogenesis of Type 1 diabetes mellitus: A brief overview. Rom J Diabetes Nutr Metab Dis 2012;19:67-72.
14. Mathieu C, van Etten E, Decallonne B, Guilietti A, Gysemans C, Bouillon R, et al. Vitamin D and 1, 25-dihydroxy Vitamin D3 as modulators in the immune system. J Steroid Biochem Mol Biol 2004;89-90:449-52.
15. Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio D. Role of Vitamin D in the pathogenesis of Type 2 diabetes mellitus. Diabetes Obes Metab 2008;10:185-97.
16. Lemire J. 1, 25-Dihydroxy Vitamin D3--a hormone with immunomodulatory properties. Z Rheumatol 2000;59 Suppl 1:24-7.
17. Goswami R, Mishra SK, Kochupillai N. Prevalence and potential significance of Vitamin D deficiency in Asian Indians. Indian J Med Res 2008;127:229-38.
18. Szodoray P, Nakken B, Gaal J, Jonsson R, Szegedi A, Zold E, et al. The complex role of Vitamin D in autoimmune diseases. Scand J Immunol 2008;68:261-9.
19. Conti P, Kempuraj D. Impact of Vitamin D on mast cell activity, immunity and inflammation. J Food Nutr Res 2016;4:33-9.
20. Harinarayan CV. Vitamin D and diabetes mellitus. Hormones Athens 2014;13:163-81.
21. Al Homsi M, Lukic M. An Update on the Pathogenesis of Diabetes Mellitus. Al Ain, United Arab Emirates: Department of Pathology and Medical Microbiology (Immunology Unit) Faculty of Medicine and Health Sciences, UAE University, 1992.
22. Cantorna MT, Mahon BD. Mounting evidence for Vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood, NJ) 2004;229:1136-42.
23. Zella JB, De Luca HF. Vitamin D and autoimmune diabetes. J Cell Biochem 2003;88:216-22.
24. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: Modulator of the immune system. Curr Opin Pharmacol 2010;10:482-96.
25. Virtanen SM, Knip M. Nutritional risk predictors of beta cell autoimmunity and Type 1 diabetes at a young age. Am J Clin Nutr 2003;78:1053-67.
26. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L. A 1alpha, 25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002;51:1367-74.
242 Views | 214 Downloads
How to Cite
Kadhim, K. A., L. T. Nafea, G. A. Gasim, E. A.- al Hameed, and H. A. Fawzi. “ASSESSMENT OF VITAMIN D THERAPY EFFECT ON INFLAMMATORY MARKERS IN PEDIATRIC PATIENTS WITH TYPE I DIABETIC”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 10, Oct. 2018, pp. 552-4, doi:10.22159/ajpcr.2018.v11i10.28936.
Original Article(s)